Literature DB >> 30103044

Recommendations and barriers to vaccination in systemic lupus erythematosus.

Megha Garg1, Naaima Mufti2, Tara N Palmore3, Sarfaraz A Hasni4.   

Abstract

Patients with Systemic Lupus Erythematosus (SLE) pose a unique dilemma pertaining to immunization against common pathogens. SLE patients are usually not immunized with vaccines based on the fear of either precipitating infection in this immunosuppressed patient population (with live vaccines) or aggravating autoimmunity and hence lupus flares (with any vaccines). However, elevated vulnerability to infection makes patients with SLE precisely the population that needs protection from vaccine-preventable diseases. A summary of guidelines from the Centers for Disease Control and Prevention, professional societies, review articles and expert opinions regarding use of individual vaccines applicable to adults with SLE is presented in this review. Published by Elsevier B.V.

Entities:  

Keywords:  Lupus; Vaccination

Mesh：

Substances：

Year:  2018        PMID： 30103044      PMCID： PMC6150817          DOI： 10.1016/j.autrev.2018.04.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


  154 in total

1.  Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history.

Authors:  Glinda S Cooper; Mary Anne Dooley; Edward L Treadwell; E William St Clair; Gary S Gilkeson
Journal:  J Clin Epidemiol       Date:  2002-10       Impact factor: 6.437

2.  The Lyme vaccine: a cautionary tale.

Authors:  E McSweegan
Journal:  Epidemiol Infect       Date:  2006-10-26       Impact factor: 2.451

Review 3.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

4.  Rotavirus vaccine withdrawal in the United states; the role of postmarketing surveillance.

Authors:  G Delage
Journal:  Can J Infect Dis       Date:  2000-01

5.  HLA-DR class II associations with rubella vaccine-induced joint manifestations.

Authors:  L A Mitchell; A J Tingle; L MacWilliam; C Horne; P Keown; L K Gaur; G T Nepom
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

6.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Authors:  Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

Review 7.  Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues.

Authors:  Mahmoud Abu-Shakra; Joseph Press; Dan Buskila; Shaul Sukenik
Journal:  Autoimmun Rev       Date:  2007-01-09       Impact factor: 9.754

8.  Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety.

Authors:  Ewa Wiesik-Szewczyk; Magdalena Romanowska; Paweł Mielnik; Hanna Chwalińska-Sadowska; Lidia B Brydak; Marzena Olesińska; Jakub Zabek
Journal:  Clin Rheumatol       Date:  2010-02-07       Impact factor: 3.650

9.  Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Authors:  Elchonon M Berkowitz; Graeme Moyle; Hans-Jürgen Stellbrink; Dirk Schürmann; Stephen Kegg; Matthias Stoll; Mohamed El Idrissi; Lidia Oostvogels; Thomas C Heineman
Journal:  J Infect Dis       Date:  2014-11-03       Impact factor: 5.226

10.  Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis.

Authors:  Zhengfa Liao; Hao Tang; Xiaojia Xu; Yaping Liang; Yongzhen Xiong; Jindong Ni
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240
View more
  4 in total

1.  Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases.

Authors:  Claire T Deakin; Georgina H Cornish; Kevin W Ng; Nikhil Faulkner; William Bolland; Joshua Hope; Annachiara Rosa; Ruth Harvey; Saira Hussain; Christopher Earl; Bethany R Jebson; Meredyth G L L Wilkinson; Lucy R Marshall; Kathryn O'Brien; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Harsita Patel; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Moira J Spyer; Steve J Gamblin; John McCauley; Eleni Nastouli; Michael Levin; Peter Cherepanov; Coziana Ciurtin; Lucy R Wedderburn; George Kassiotis
Journal:  Med (N Y)       Date:  2021-08-14

2.  The COVID-19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases.

Authors:  Jiali Chen; Wenxin Cai; Tian Liu; Yunshan Zhou; Yuebo Jin; Yue Yang; Shi Chen; Kun Tang; Chun Li
Journal:  Rheumatol Autoimmun       Date:  2022-02-15

3.  Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus.

Authors:  Yanming Cui; Jianbo Wei; Xiang Peng
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

4.  Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Kar Li Chan; Sau Mei Tse
Journal:  Vaccine       Date:  2022-09-06       Impact factor: 4.169
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.